This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
by Zacks Equity Research
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck (MRK) Resumes HIV Studies on Islatravir With Lower Dose
by Zacks Equity Research
Merck's (MRK) new phase III studies are set to evaluate a once-daily oral combination of doravirine and a lower dose of islatravir
Merck (MRK) Stock Moves -0.74%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $86 in the latest trading session, marking a -0.74% move from the prior day.
Merck's (MRK) Pneumococcal Jab Gets CHMP Endorsement for Kids
by Zacks Equity Research
The EMA's CHMP recommends approving Merck's (MRK) pneumococcal 15-valent conjugate vaccine for expanded use in infants and children. The vaccine received similar approval from the FDA in June 2022.
Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval
by Zacks Equity Research
Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.
The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca
by Zacks Equity Research
AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.
Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study
by Zacks Equity Research
Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.
4 Large Drug Stocks to Watch as Fundamentals Stay Strong
by Kinjel Shah
Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.
The Zacks Analyst Blog Highlights Merck, Cisco, Morgan Stanley, CME Group and Canadian Natural Resources
by Zacks Equity Research
Merck, Cisco, Morgan Stanley, CME Group and Canadian Natural Resources are included in this Analyst Blog.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $86.95 in the latest trading session, marking a +0.78% move from the prior day.
Top Analyst Reports for Merck, Cisco & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Cisco Systems, Inc. (CSCO) and Morgan Stanley (MS).
Corcept (CORT) Up More Than 20% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Key Factors Driving Merck's (MRK) Outperformance This Year
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $87.42 in the latest trading session, marking a +0.63% move from the prior day.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Emergent (EBS) Initiates Study on Lassa Virus Vaccine Candidate
by Zacks Equity Research
Emergent BioSolutions (EBS) initiates an early-stage study evaluating its Lassa virus vaccine candidate, EBS-LASV, for the prevention of Lassa fever.
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Merck (MRK) Stock Moves -1.06%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $86.23, marking a -1.06% move from the previous day.
3 Stocks to Buy in September as the Market Falls and Rates Rise
by Benjamin Rains
Diving into three dividend-paying stocks that could be poised to help investors profit in September and beyond.
Company News for Aug 29, 2022
by Zacks Equity Research
Companies in The News Are: AFRM,FTCH,SGEN,MRK,DELL
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
by Zacks Equity Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.